Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?

被引：219

作者：

Freitas-Junior, Lucio H. ^{[1
]}

Chatelain, Eric ^{[2
]}

Kim, Helena Andrade ^{[1
]}

Siqueira-Neto, Jair L. ^{[1
]}

机构：

[1] Inst Pasteur Korea, Ctr Neglected Dis Drug Discovery, Songnam, Gyeonggi Do, South Korea

[2] Drugs Neglected Dis Initiat, CH-1202 Geneva, Switzerland

来源：

INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE | 2012年 / 2卷

关键词：

Leishmania; Leishmaniasis; Drug discovery; High throughput screening; LIPOSOMAL AMPHOTERICIN-B; HIGH-THROUGHPUT; DRUG TARGETS; PENTAVALENT ANTIMONIALS; MEGLUMINE ANTIMONIATE; IN-VITRO; DONOVANI; DISEASE; IDENTIFICATION; MILTEFOSINE;

D O I：

10.1016/j.ijpddr.2012.01.003

中图分类号：

R38 [医学寄生虫学]; Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ; 100103 ;

摘要：

Leishmaniasis is one of the most neglected tropical disease in terms of drug discovery and development. Most antileishmanial drugs are highly toxic, present resistance issues or require hospitalization, being therefore not adequate to the field. Recently improvements have been achieved by combination therapy, reducing the time and cost of treatment. Nonetheless, new drugs are still urgently needed. In this review, we describe the current visceral leishmaniasis (VL) treatments and their limitations. We also discuss the new strategies in the drug discovery field including the development and implementation of high-throughput screening (HTS) assays and the joint efforts of international teams to deliver clinical candidates. (C) 2012 Australian Society for Parasitology Published by Elsevier Ltd. All rights reserved.

引用

页码：11 / 19

页数：9

共 99 条

[1] Genomic-scale prioritization of drug targets: the TDR Targets database [J].

Agueero, Fernan ;

Al-Lazikani, Bissan ;

Aslett, Martin ;

Berriman, Matthew ;

Buckner, Frederick S. ;

Campbell, Robert K. ;

Carmona, Santiago ;

Carruthers, Ian M. ;

Chan, A. W. Edith ;

Chen, Feng ;

Crowther, Gregory J. ;

Doyle, Maria A. ;

Hertz-Fowler, Christiane ;

Hopkins, Andrew L. ;

McAllister, Gregg ;

Nwaka, Solomon ;

Overington, John P. ;

Pain, Arnab ;

Paolini, Gala V. ;

Pieper, Ursula ;

Ralph, Stuart A. ;

Riechers, Aaron ;

Roos, David S. ;

Sali, Andrej ;

Shanmugam, Dhanasekaran ;

Suzuki, Takashi ;

Van Voorhis, Wesley C. ;

Verlinde, Christophe L. M. J. .

NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (11) :900-907

[2] Chemotherapy in the treatment and control of leishmaniasis [J].

Alvar, Jorge ;

Croft, Simon ;

Olliaro, Piero .

ADVANCES IN PARASITOLOGY, VOL 61: CONTROL OF HUMAN PARASITIC DISEASES, 2006, 61 :223-+

[3]

[Anonymous], 1990, World Health Organ Tech Rep Ser, V793, P1

[4]

[Anonymous], 2007, 5 CONS M LEISHM HIV

[5] Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening [J].

Ashutosh ;

Gupta, S ;

Ramesh ;

Sundar, S ;

Goyal, N .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (09) :3776-3783

[6] Molecular mechanisms of antimony resistance in Leishmania [J].

Ashutosh ;

Sundar, Shyam ;

Goyal, Neena .

JOURNAL OF MEDICAL MICROBIOLOGY, 2007, 56 (02) :143-153

[7] Putrescine and spermidine transport in Leishmania [J].

Basselin, M ;

Coombs, GH ;

Barrett, MP .

MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 2000, 109 (01) :37-46

[8]

Berman JD, 1998, B WORLD HEALTH ORGAN, V76, P25

[9] Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India [J].

Bhattacharya, SK ;

Jha, TK ;

Sundar, S ;

Thakur, CP ;

Engel, J ;

Sindermann, H ;

Junge, K ;

Karbwang, J ;

Bryceson, ADM ;

Berman, JD .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (02) :217-221

[10] The beautiful cell: high-content screening in drug discovery [J].

Bickle, Marc .

ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2010, 398 (01) :219-226

← 1 2 3 4 5 6 7 8 9 10 →